Last reviewed · How we verify
Normal saline, Lidocaine, dexmetomidine
This is a combination formulation of normal saline (isotonic fluid), lidocaine (local anesthetic), and dexmedetomidine (alpha-2 adrenergic agonist) used for local anesthesia and sedation.
This is a combination of normal saline (fluid replacement), lidocaine (local anesthetic blocking nerve conduction), and dexmedetomidine (alpha-2 adrenergic agonist producing sedation and analgesia). Used for Local anesthesia with sedation for procedures, Perioperative sedation and analgesia.
At a glance
| Generic name | Normal saline, Lidocaine, dexmetomidine |
|---|---|
| Sponsor | Kasr El Aini Hospital |
| Drug class | Local anesthetic combination with sedative-analgesic agent |
| Target | Voltage-gated sodium channels (lidocaine); alpha-2 adrenergic receptors (dexmedetomidine) |
| Modality | Small molecule |
| Therapeutic area | Anesthesia, Sedation, Pain Management |
| Phase | FDA-approved |
Mechanism of action
Normal saline provides an isotonic vehicle. Lidocaine blocks sodium channels in nerve fibers to produce local anesthesia and pain relief. Dexmedetomidine is a selective alpha-2 adrenergic agonist that produces sedation, analgesia, and anxiolysis by acting on central and peripheral alpha-2 receptors.
Approved indications
- Local anesthesia with sedation for procedures
Common side effects
- Hypotension
- Bradycardia
- Dry mouth
- Sedation
- Local injection site reactions
Key clinical trials
- Dexmedetomidine and Dexamethasone Added as Adjuvant Infraclavicular Brachial Plexus Block in Upper Limb Surgery
- Evaluation of Lidocaine Spray Versus Dexmetomidine Spray on Stress Response (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: